Evidence Level
CBD has garnered significant attention for its potential benefits in managing anxiety and sleep, though evidence remains emerging. A 2024 systematic review and meta-analysis by Han et al., involving 316 participants across eight studies, demonstrated that CBD significantly reduces anxiety (Hedges' g = -0.92). This aligns with earlier findings from Linares et al. (2019), who reported an inverted U-shaped dose-response curve for acute anxiety, peaking at 300mg in a simulated public speaking test. Zuardi et al. (1993) provided foundational evidence of CBD's anxiolytic effects in a similar experimental setting.
The evidence for sleep improvement is less robust, with most studies noting such benefits as secondary outcomes linked to anxiety reduction. Regulatory inconsistencies remain a concern, with significant variability in CBD product quality. Additionally, CBD interacts with CYP450 enzymes (e.g., CYP3A4, CYP2C9, and CYP2C19), potentially affecting drug metabolism, as highlighted by Dos Santos et al. (2026). The FDA has only approved CBD (as Epidiolex) for specific epilepsy conditions, not for anxiety or sleep.
Recent studies also explore CBD's broader therapeutic potential. Duan et al. (2026) conducted a systematic review of 15 preclinical studies, finding that CBD inhibits tumor growth and metastasis across multiple cancer types through multi-target mechanisms. However, the limited number of large, well-designed RCTs for anxiety and sleep remains a critical gap in the evidence base.